761P Tumor infiltrating lymphocytes expressing membrane-bound IL-2 and IL-12 exhibit enhanced proliferation, function, and persistence without requiring exogenous IL-2 support

Abstract

Tumor Infiltrating Lymphocyte (TIL) therapies have shown significant solid tumor activity in patients, but many current TIL regimens require lymphodepletion and high-dose IL-2 after cell infusion to support TIL persistence and clinical activity. Removing these requirements that cause systemic toxicity while maintaining or improving TIL product functionality by ex vivo engineering of the TIL product with transient expression of mRNA could dramatically improve the patient experience, expand the eligible patient population, and potentially allow repeat dosing.